Serum sclerostin levels in osteoporotic fracture patients

Gorter, Erwin A.; Reinders, C.R.; Krijnen, Pieta; Appelman‐Dijkstra, Natasha M.; Schipper, I.B.

doi:10.1007/s00068-022-02017-7

Cited by 4 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sclerostin is predominantly synthesized by osteocytes; a possible explanation of the lower levels of sclerostin in osteoporotic patients is the age-dependent reduction in osteocyte number/density and change in morphology. This alteration might result in a decreased functioning of the osteocyte, including the production of sclerostin [ 14 ].…”

Section: Resultsmentioning

confidence: 99%

Serum sclerostin levels as a diagnostic marker for osteoporosis

Paranthaman

2024

Bioinformation

View full text Add to dashboard Cite

Osteoporosis is asymptomatic, in which low bone-mass and micro-architectural deterioration of bone tissue leads to increasing bone fragility and fracture. Vertebral and hip fractures lead to increased mortality, resulting in enormous health care costs. BMD testing by DEXA is used in diagnosis of osteoporosis. However, low-and middle-income populations are unable to conduct periodic examinations of bone mineral status. Thus, current study is mainly aimed at finding a cost-effective diagnostic-marker for osteoporosis. 170 participants, of whom 51 had osteoporosis, 62 had osteopenia and 57 had normal bone-mass. Selection of individuals was based on DEXA scan BMD. Sclerostin was determined by ELISA. The variables were compared using ANOVA test and ROC analysis was performed. Sclerostin levels were significantly decreased in osteoporosis (4.62 ą 1.6 ng/mL) and osteopenia (4.92 ą 1.4 ng/mL) compared with controls (5.74 ą 1.3 ng/mL), (p < 0.0001). Sclerostin level 5.6 ng/mL is the cut-off value for diagnostic purpose, according to good sensitivity and specificity. In patients with osteopenia and osteoporosis, decreased sclerostin levels were associated with an increased disease risk. These relationships were independent of BMD and bone turnover, suggesting that Sclerostin levels may reflect disease-severity in osteoporosis. Sclerostin measurements could become a useful clinical index for diagnosis of osteoporosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Serum sclerostin levels as a diagnostic marker for osteoporosis

Paranthaman

2024

Bioinformation

View full text Add to dashboard Cite

show abstract

“…Notably, postmenopausal women demonstrate increased sclerostin levels [ 59 ]. Although it might be expected that sclerostin and Dkk1 are inversely correlated with BMD in postmenopausal women, several studies have revealeda positive association between BMD and sclerostin and Dkk1 [ 60 , 61 , 62 ]. For instance, a recent study found a positive correlation between sclerostin and Dkk1 expression in bone from postmenopausal women with osteoporosis and BMD, with their serum levels reflecting their bone levels [ 60 ].…”

Section: Novel Bone Markersmentioning

confidence: 99%

Novel Biomarkers of Bone Metabolism

Fernández-Villabrille,

Martín-Carro,

Martín-Vírgala

et al. 2024

Nutrients

View full text Add to dashboard Cite

Bone represents a metabolically active tissue subject to continuous remodeling orchestrated by the dynamic interplay between osteoblasts and osteoclasts. These cellular processes are modulated by a complex interplay of biochemical and mechanical factors, which are instrumental in assessing bone remodeling. This comprehensive evaluation aids in detecting disorders arising from imbalances between bone formation and reabsorption. Osteoporosis, characterized by a reduction in bone mass and strength leading to heightened bone fragility and susceptibility to fractures, is one of the more prevalent chronic diseases. Some epidemiological studies, especially in patients with chronic kidney disease (CKD), have identified an association between osteoporosis and vascular calcification. Notably, low bone mineral density has been linked to an increased incidence of aortic calcification, with shared molecules, mechanisms, and pathways between the two processes. Certain molecules emerging from these shared pathways can serve as biomarkers for bone and mineral metabolism. Detecting and evaluating these alterations early is crucial, requiring the identification of biomarkers that are reliable for early intervention. While traditional biomarkers for bone remodeling and vascular calcification exist, they suffer from limitations such as low specificity, low sensitivity, and conflicting results across studies. In response, efforts are underway to explore new, more specific biomarkers that can detect alterations at earlier stages. The aim of this review is to comprehensively examine some of the emerging biomarkers in mineral metabolism and their correlation with bone mineral density, fracture risk, and vascular calcification as well as their potential use in clinical practice.

show abstract

“…Recently, many studies have been conducted on the role of sclerostin and Wnt signaling in the treatment of osteoporosis [17,18]. However, there are still many uncertainties about the effect of sclerostin, and in particular, there are not many studies on the correlation between sclerostin and risedronate, including bisphosphonates.…”

Section: Introductionmentioning

confidence: 99%

Osteoclast and Sclerostin Expression in Osteocytes in the Femoral Head with Risedronate Therapy in Patients with Hip Fractures: A Retrospective Comparative Study

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: The majority of research on the effects of osteoporosis drugs has measured the bone mineral density (BMD) of the spine and femur through dual-energy X-ray absorptiometry (DEXA) and compared and analyzed the effects of the drugs through changes in the BMD values. This study aims to compare osteoclast and sclerostin expression in osteocytes after risedronate therapy by obtaining femoral heads from patients with hip fractures. Materials and Methods: We obtained the femoral heads of 10 female patients (age: ≥65 years) who received risedronate therapy for at least 1 year through hip arthroplasty during 2019–2021 (risedronate group). Meanwhile, 10 patients who had never received osteoporosis treatment were selected as controls using propensity scores with age, body mass index, and bone density as covariates (control group). While the osteoclast count was evaluated using tartrate-resistant acid phosphatase (TRAP) staining, the sclerostin expression in osteocytes was assessed using immunohistochemistry. Moreover, Western blotting and polymerase chain reaction (PCR) were performed for receptor activation of nuclear factor kappa-Β ligand (RANKL), RANK, osteoprotegerin (OPG), sclerostin, and bone morphogenetic protein-2 (BMP2). Results: TRAP staining revealed significantly more TRAP-positive cells in the control group (131.75 ± 27.16/mm2) than in the risedronate group (28.00 ± 8.12/mm2). Moreover, sclerostin-positive osteocytes were expressed more in the control group (364.12 ± 28.12/mm2) than in the risedronate group (106.93 ± 12.85/mm2). Western blotting revealed that the expressions of RANKL, RANK, sclerostin, and BMP2 were higher in the control group than in the risedronate group (p < 0.05). Furthermore, RANK, sclerostin, and OPG protein levels were higher in the control group than in the risedronate group. Conclusions: In this study, the risedronate group demonstrated lower osteoclast activity and sclerostin expression in osteocytes in the femoral head than the control group.

show abstract

Serum sclerostin levels in osteoporotic fracture patients

Cited by 4 publications

References 57 publications

Serum sclerostin levels as a diagnostic marker for osteoporosis

Serum sclerostin levels as a diagnostic marker for osteoporosis

Novel Biomarkers of Bone Metabolism

Osteoclast and Sclerostin Expression in Osteocytes in the Femoral Head with Risedronate Therapy in Patients with Hip Fractures: A Retrospective Comparative Study

Contact Info

Product

Resources

About